Professor, Department of Pathology, Microbiology
and Immunology and Department of Otolaryngology
Resident Research Coordinator, Department of Otolaryngology
Course Director, Medical Microbiology
Regional Vice President, Executive Committee of Faculty Senate
Member, Executive Committee of Education and Curriculum
Email: jan_geliebter@nymc.edu
Address:
Dept. of Pathology, Microbiology & Immunology
Basic Sciences Building Room 311
New York Medical College
Valhalla, NY 10595
Professional Interests:
The focus of our research is the molecular pathogenesis of papillary thyroid cancer (PTC). We are using RNASeq to interrogate the landscape of gene expression alteration in PTC in clinical samples. By comparing PTC and samples of normal tissues from the same patients we have gained insight into the molecular changes driving PTC, as well as potential therapeutic targets. As men have a lower incidence of PTC than women, we are concentrating on the role of androgens in the etiology and progression of PTC. Our results indicate that androgens exert an anti-proliferative effect and result in a G1-S block in the cancer cell cycle.
Education Profile:
Graduate Degree: Ph.D.
Graduate Degree Institution: State University of New York Health Science Center at Brooklyn
Undergraduate Institution: Hebrew University of Jerusalem, Israel, BSc, Biology
Selected Bibliography:
Shilpi Rajoria, Robert Suriano, ArulKumaran Shanmugam, Andrea George, Stimson Schantz, Jan Geliebter, and Raj Tiwari. 2011 3,3'-diindolylmethane inhibits estrogen mediated metastatic propensity of thyroid cancer. Thyroid. 20:33-41.
Theodore S. Nowicki, Hong Zhao, Zbigniew Darzynkiewicz,, Stimson Schantz, Edward Shin, Raj K. Tiwari, and Jan Geliebter. 2011 Down-regulation of uPAR inhibits migration, invasion, proliferation, and FAK/PI3K/Akt signaling in papillary thyroid carcinoma cells. Cell Cycle. 10:100–107.
Rajoria S, Suriano R, Wilson YL, Schantz SP, Moscatello A, Geliebter J, Tiwari RK. 2011. 3,3’-diindolylmethane inhibits migration and invasion of human cancer cells through combined suppression of ERK and AKT pathways. Oncology Reports. 25: 491-497.
Rajoria S, Suriano R, Wilson YL, Schantz SP, Moscatello A, Geliebter J, Tiwari RK. 2011. Metastatic modulators MMP2/MMP9 are targets of the antiestrogen DIM in thyroid cancer: Implication for cancer prevention and diagnosis. PLOS ONE. 6:1-11.
Theodore S. Nowicki, Augustine L. Moscatello, Edward Shin, Stimson Schantz, Raj K. Tiwari, and Jan Geliebter 2011. The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target. J Clin Endo Metab. . J Clin Endo Metab. 2011 96:3062-3064
E.Ashlie Darr, Anand D. Patel, Zbigniew Komorowski, Steven McCormick Stimson P. Schantz, Raj Tiwari and Jan Geliebter. 2011. Reduced Cx43 Expression Differentiates Follicular Thyroid Carcinoma from Follicular Adenoma. Arch. Otolaryngol, Head Neck Surg 137: 1-5
Nicolas T. Kummer, Theodore Nowicki, Ismael Reyes, Codrin Iacob, Nina Suslina, Steven Schaefer, Stimson Schantz, Michal L. Schwartzman, Raj K. Tiwari, and Jan Geliebter. 2012 Arachidonate 5 Lipoxygenase Expression in Papillary Thyroid Carcinoma Promotes Invasion via MMP-9 Induction. Journal of Cellular Biochemistry 113: 1987 – 1997.
Rajoria S, Suriano R, George AL, Shanmugam A, Jussim C, Shin EJ, Moscatello AL, Geliebter J, Carpi A, Tiwari RK. 2012. Estrogen activity as a preventive and therapeutic target in thyroid cancer. Biomed Pharmacother. 66:151-8
Kenneth M. Wong, T. Scott Nowicki, Carmelo Puccio, Tauseef Ahmed, Raj Tiwari, Jan Geliebter, Augustine Moscatello. 2012. Clinical Response with Sunitinib Therapy in the Treatment of Anaplastic Thyroid Cancer Journal of Cancer Therapy, 3: 132 – 136.
Shilpi Rajoria, Robert Suriano, Andrea L George, Ameet Kamat, Stimson P Schantz, Jan Geliebter, Raj K Tiwari. 2012 Molecular target based combinational therapeutic approaches in thyroid cancer. Journal of Translational Medicine . J Transl Med. 2012; 10:81.
Suriano R, Rajoria S, George AL, Geliebter J, Tiwari RK, Wallack M. Follow‑up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma. 2013 Mol and Clin Oncology. 1:466-472
Suriano R, Rajoria S, L George A, Geliebter J, Wallack M, Tiwari RK. 2013 Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines 2013. J of Cancer. 4:371-82.
Hanly EK, Rajoria S, Darzynkiewicz Z, Zhao H, Suriano R, Tuli N, George AL, Bednarczyk R, Shin EJ, Geliebter J, Tiwari RK. Disruption of mutated BRAF signaling modulates thyroid cancer phenotype. 2014 BMC Res Notes. Mar 28;7:187. doi: 10.1186/1756-0500-7-187. PMID: 24673746
Rajoria S, Hanly E, Nicolini A, George AL, Geliebter J, Shin EJ, Suriano R, Carpi A, Tiwari RK. Interlinking of hypoxia and estrogen in thyroid cancer progression. 2014 Current Medicinal Chemistry 21(11):1351-60. PMID: 24304276
Hanly, Elyse , Robert Bednarczyk , Neha Tuli , Augustine Moscatello , H Dorota Halicka , Jiangwei Li , Jan Geliebter , Zbigniew Darzynkiewicz Raj Tiwari. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. 2014 BMC Research Notes, 7:187
Reyes N1, Bettin A1, Reyes I2, Geliebter J3.Microarray analysis of the in vitro granulomatous response to Mycobacterium tuberculosis H37Ra. 2015 Colomb Med (Cali). Mar 30;46(1):26-32. PMID: 26019382 [PubMed - in process] PMCID:PMC4437284
George AL, Suriano R, Rajoria S, Osso MC, Tuli N, Hanly E, Geliebter J, Arnold AN, Wallack M, Tiwari R.K.. PLX4032 mediated melanoma associated antigen potentiation in patient derived melanoma cells. J Cancer 2015;6(12):1320-30.
Reyes, Niradiz, Ines Benedett, Alfonso Bettin, Juan Rebollo, Geliebter, Jan. The small leucine rich proteoglycan fibromodulin is overexpressed in human prostate epithelial cancer cell lines in culture and human prostate cancer tissue 2016 Cancer Biomark. 2016;16(1):191-202. doi: 10.3233/CBM-150555.
Hanly EK, Tuli NY, Bednarczyk RB, Suriano R, Geliebter J, Moscatello AL, Darzynkiewicz Z, Tiwari RK. Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells. 2016 Oncotarget. 2016 Feb 23;7(8):8676-87.
Choi D, Ramu S, Park E, Jung E, Yang S, Jung W, Choi I, Lee S, Kim KE, Seong YJ, Hong M, Daghlian G, Kim D, Shin E, Seo JI, Khatchadourian V, Zou M, Li W, De Filippo R, Kokorowski P, Chang A, Kim S, Bertoni A, Furlanetto TW, Shin S, Li M, Chen Y, Wong A, Koh C, Geliebter J, Hong YK. Aberrant Activation of Notch Signaling Inhibits PROX1 Activity to Enhance the Malignant Behavior of Thyroid Cancer Cells. 2016 Cancer Res. 2016 Feb 1;76(3):582-93. doi: 10.1158/0008-5472.CAN-15-1199.
Tuli, N., Maniyar, R., Bednarczyk,R., Ben Rahoma, G., Singh, S., Geliebter, J., Mittelman, A., Wallack, M., Banerjee, D., Tiwari R.K. Cancer Vaccines: Bench to Bedside. International Journal of Translational Science, Vol. 2016(1),Article 3: 33–60
Search PubMed for all available publications of Jan Geliebter, Ph.D.